See more : Morningstar Japan K.K. (4765.T) Income Statement Analysis – Financial Results
Complete financial analysis of MoonLake Immunotherapeutics (MLTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MoonLake Immunotherapeutics, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Beacon Rise Holdings PLC (BRS.L) Income Statement Analysis – Financial Results
- 17 Education & Technology Group Inc. (YQ) Income Statement Analysis – Financial Results
- Empire State Realty OP, L.P. (OGCP) Income Statement Analysis – Financial Results
- Brookfield Property Preferred L.P. (BPYPM) Income Statement Analysis – Financial Results
- Shenzhen JT Automation Equipment Co.,Ltd (300400.SZ) Income Statement Analysis – Financial Results
MoonLake Immunotherapeutics (MLTX)
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 13.16K | 12.36K | 4.97K | 0.00 |
| Gross Profit | -13.16K | -12.36K | -4.97K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 31.80M | 42.05M | 35.52M | 0.00 |
| General & Administrative | 22.32M | 23.01M | 21.66M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 18.03M | 0.00 |
| SG&A | 22.32M | 23.01M | 18.05M | 105.76K |
| Other Expenses | 0.00 | 591.73K | 0.00 | 0.00 |
| Operating Expenses | 54.12M | 65.06M | 53.57M | 105.76K |
| Cost & Expenses | 54.12M | 65.06M | 53.58M | 105.76K |
| Interest Income | 0.00 | 0.00 | 0.00 | 14.92K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 13.16K | 12.36K | 4.97K | 206.30K |
| EBITDA | -54.11M | -65.05M | -53.63M | -90.84K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -54.12M | -65.06M | -53.58M | -105.76K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.14M | 591.73K | 10.65M | 14.92K |
| Income Before Tax | -43.98M | -64.47M | -53.64M | -90.84K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 94.39K | 36.37K | 4.76K | -206.30K |
| Net Income | -36.01M | -64.51M | -53.64M | -90.84K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.73 | -2.20 | -6.84 | -0.01 |
| EPS Diluted | -0.73 | -2.20 | -6.84 | -0.01 |
| Weighted Avg Shares Out | 49.12M | 29.36M | 7.84M | 14.81M |
| Weighted Avg Shares Out (Dil) | 49.12M | 29.36M | 7.84M | 14.81M |
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody ® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
The 7 Best Momentum Stocks You Can Purchase Today
If you're looking for some of the hottest opportunities on the market, consider some of the best momentum stocks to buy. After all, momentum investors try to ride the highs no matter what happens.
Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade
The consensus price target hints at a 27% upside potential for MoonLake Immunotherapeutics (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...
Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now?
MoonLake Immunotherapeutics (MLTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
MoonLake Immunotherapeutics Is A Promising Bet On Psoriasis Treatment
MoonLake Immunotherapeutics is a Swiss biopharmaceutical company focused on nanobody development with its drug Sonelokimab. Sonelokimab has shown positive results in clinical trials for psoriasis, hidradenitis suppurativa, and psoriatic arthritis. The market for IL-17 inhibitors, like Sonelokimab, is projected to...
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing the Nanobody ® sonelokimab as a highly promising and differentiated therapeutic solution for...
MoonLake Immunotherapeutics stock craters after arthritis treatment study disappoints
MoonLake Immunotherapeutics shares swooned Monday after the company reported ambiguous results for its psoriatic arthritis treatment. Patients who received MoonLake's drug, sonelokimab, did show statistically significant improvements, but patients receiving a placebo saw better-than-expected results.
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody ® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody ® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (HS)
Source: https://incomestatements.info
Category: Stock Reports